| Diagram | Status
How It Works
SmartInsulin™ consists of a layered, biocompatible and biodegradable polymer-therapeutic that is bound to an engineered glucose-binding molecule. Insulin is released from SmartInsulin only when the therapeutic is unbound by the presence of a specific glucose concentration.
The base patent was filed in 2003 and SmartCells holds an exclusive license to the technology from MIT, where the company's founders developed the technology on which SmartInsulin is based. Other applications of this technology include:
» Endocrine disorders such as fertility, thyroid and growth hormone deficiencies
» Treatments with poor compliance or therapeutic window issues, e.g. oncology
» Drug-device combinations such as event-triggered thrombolytic-eluting stents